While the USPTO updated its cannabis trademark guidance in the wake of the 2018 Farm Bill, it didn’t give the green light to all CBD-related trademarks…
While the U.S. Patent and Trademark Office’s (USPTO) updated its cannabis trademark guidance in the wake of the 2018 Farm Bill, it didn’t give the green light to all CBD-related trademarks. As highlighted by a recent decision by the Trademark Trial and Appeal Board (TTAB), legal hurdles still remain.
2018 Farm Bill and Cannabis Marks
As discussed in greater detail in prior articles, the 2018 Farm Bill removed “hemp” from the Controlled Substances Act’s (CSA) definition of marijuana, which means that cannabis plants and derivatives that contain no more than 0.3% THC on a dry-weight basis are no longer controlled substances under the CSA. The significant legal change forced the USPTO to revise its wholesale refused to register cannabis-related marks based on the fact that it was illegal under federal law.
Last year, the USPTO issued a new examination guide titled “Examination of Marks for Cannabis and Cannabis-Related Goods and Services after Enactment of the 2018 Farm Bill (Examination Guide). As the USPTO acknowledged in the Examination Guide, determining whether commerce involving cannabis and cannabis-related goods and services is lawful now requires consultation of the CSA, the Federal Food Drug and Cosmetic Act (FDCA), and the 2018 Farm Bill. With regard to the examination of marks for cannabis and cannabis-derived goods, such as CBD, the USPTO advises that hemp-derived goods that comply with the 2018 Farm Bill are now eligible for federal trademark protection. However, for a trademark application to be approved, the identification of goods must specify that they contain less than 0.3% THC.
Accordingly, the USPTO makes it clear that its new guidance only applies to goods derived from hemp. “Cannabis and CBD derived from marijuana (i.e., Cannabis sativa L. with more than 0.3% THC on a dry-weight basis) still violate federal law, and applications encompassing such goods will be refused registration regardless of the filing date,” the Examination Guide states.
The USPTO further emphasizes that even if the identified goods are legal under the CSA, such goods may still raise lawful-use issues under the FDCA. Accordingly, registration of marks for foods, beverages, dietary supplements, or pet treats containing CBD will still be refused as unlawful under the FDCA, even if derived from hemp, because they may not be introduced lawfully into interstate commerce.
TTAB Rejects CBD Mark
The new USPTO Examination Guide means that many marks associated with products containing CBD can now be protected. However, as a Colorado cannabis company learned, there are still restrictions.
The TTAB recently ruled that Stanley Brothers Social Enterprises LLC (Stanley) can’t register the mark “CW” for its hemp oil extract because the product can’t legally be sold in commerce. While the CBD in the product is considered industrial hemp, the product runs afoul of the Food, Drug & Cosmetics Act (FDCA) because the “hemp oil extracts” are food to which CBD has been added. The FDCA prohibits “[t]he introduction or delivery for introduction into interstate commerce of any food to which has been added … a drug or biological product for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public ….”
In reaching its decision, the TTAB rejected Stanley’s counterarguments that the 2014 Farm Bill’s Industrial Hemp Provision exempted it from the cited provision of the FDCA and that its goods do not fall within the cited prohibition because they are “dietary supplements” rather than food. “Applicant’s argument that the Industrial Hemp Provision exempts it from this portion of the FDCA is misplaced,” the order states. “The Industrial Hemp Provision permits authorized entities to “grow or cultivate industrial hemp” under certain circumstances, but it does not permit the distribution or sale of CBD in food when CBD is the subject of clinical investigation, even if the CBD is derived from industrial hemp which falls outside the CSA.”
The TTAB also rejected the argument that CBD falls within an FDCA exception for drugs or biological products “marketed in food … before any substantial clinical investigations involving the drug or the biological product have been instituted.” In support, the TTAB cited “substantial clinical investigations” by the FDA.
Based on the foregoing, the TTAB affirmed the Examining Attorney’s unlawful use refusal based on the FDCA. “The Examining Attorney has established a per se violation of the FDCA, because: Applicant’s goods are food to which has been added a drug (CBD); substantial clinical investigations of CBD have been instituted, and the existence of these investigations has been made public; and there is no evidence of record that CBD was marketed in food before the substantial clinical investigations of CBD were instituted,” the TTAB order states.
Key Takeaway
The recent TTAB decision highlights that cannabis companies still face hurdles when seeking to protect their intellectual property. While the 2018 Farm Bill was a significant step forward, it legalized only a specific segment of hemp-related products and, thus, many cannabis products are still ineligible for federal trademark protection.
If you have questions, please contact us
If you have any questions or if you would like to discuss the matter further, please contact me, Dan McKillop, or the Scarinci Hollenbeck attorney with whom you work, at 201-896-4100.
This article is a part of a series pertaining to cannabis legalization in New Jersey and the United States at large. Prior articles in this series are below:
Disclaimer: Possession, use, distribution, and/or sale of cannabis is a Federal crime and is subject to related Federal policy. Legal advice provided by Scarinci Hollenbeck, LLC is designed to counsel clients regarding the validity, scope, meaning, and application of existing and/or proposed cannabis law. Scarinci Hollenbeck, LLC will not provide assistance in circumventing Federal or state cannabis law or policy, and advice provided by our office should not be construed as such.
Does Your Homeowners Insurance Provide Adequate Coverage?
Your home is likely your greatest asset, which is why it is so important to adequately protect it. Homeowners insurance protects you from the financial costs of unforeseen losses, such as theft, fire, and natural disasters, by helping you rebuild and replace possessions that were lost While the definition of “adequate” coverage depends upon a […]
Understanding the Importance of a Non-Contingent Offer
Making a non-contingent offer can dramatically increase your chances of securing a real estate transaction, particularly in competitive markets like New York City. However, buyers should understand that waiving contingencies, including those related to financing, or appraisals, also comes with significant risks. Determining your best strategy requires careful analysis of the property, the market, and […]
Fred D. Zemel Appointed Chair of Strategic Planning at Scarinci & Hollenbeck, LLC
Business Transactional Attorney Zemel to Spearhead Strategic Initiatives for Continued Growth and Innovation Little Falls, NJ – February 21, 2025 – Scarinci & Hollenbeck, LLC is pleased to announce that Partner Fred D. Zemel has been named Chair of the firm’s Strategic Planning Committee. In this role, Mr. Zemel will lead the committee in identifying, […]
Novation Agreement Process: Step-by-Step Guide for Businesses
Big changes sometimes occur during the life cycle of a contract. Cancelling a contract outright can be bad for your reputation and your bottom line. Businesses need to know how to best address a change in circumstances, while also protecting their legal rights. One option is to transfer the “benefits and the burdens” of a […]
What Is a Trade Secret? Key Elements and Legal Protections Explained
What is a trade secret and why you you protect them? Technology has made trade secret theft even easier and more prevalent. In fact, businesses lose billions of dollars every year due to trade secret theft committed by employees, competitors, and even foreign governments. But what is a trade secret? And how do you protect […]
What Is Title Insurance? Safeguarding Against Title Defects
If you are considering the purchase of a property, you may wonder — what is title insurance, do I need it, and why do I need it? Even seasoned property owners may question if the added expense and extra paperwork is really necessary, especially considering that people and entities insured by title insurance make fewer […]
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.
Sign up to get the latest from our attorneys!
Explore What Matters Most to You.
Consider subscribing to our Firm Insights mailing list by clicking the button below so you can keep up to date with the firm`s latest articles covering various legal topics.
Stay informed and inspired with the latest updates, insights, and events from Scarinci Hollenbeck. Our resource library provides valuable content across a range of categories to keep you connected and ahead of the curve.
Understanding How the USPTO’s Examination Guide for Cannabis Marks Impacts CBD Products
Author: Daniel T. McKillop
While the USPTO updated its cannabis trademark guidance in the wake of the 2018 Farm Bill, it didn’t give the green light to all CBD-related trademarks…
While the U.S. Patent and Trademark Office’s (USPTO) updated its cannabis trademark guidance in the wake of the 2018 Farm Bill, it didn’t give the green light to all CBD-related trademarks. As highlighted by a recent decision by the Trademark Trial and Appeal Board (TTAB), legal hurdles still remain.
2018 Farm Bill and Cannabis Marks
As discussed in greater detail in prior articles, the 2018 Farm Bill removed “hemp” from the Controlled Substances Act’s (CSA) definition of marijuana, which means that cannabis plants and derivatives that contain no more than 0.3% THC on a dry-weight basis are no longer controlled substances under the CSA. The significant legal change forced the USPTO to revise its wholesale refused to register cannabis-related marks based on the fact that it was illegal under federal law.
Last year, the USPTO issued a new examination guide titled “Examination of Marks for Cannabis and Cannabis-Related Goods and Services after Enactment of the 2018 Farm Bill (Examination Guide). As the USPTO acknowledged in the Examination Guide, determining whether commerce involving cannabis and cannabis-related goods and services is lawful now requires consultation of the CSA, the Federal Food Drug and Cosmetic Act (FDCA), and the 2018 Farm Bill. With regard to the examination of marks for cannabis and cannabis-derived goods, such as CBD, the USPTO advises that hemp-derived goods that comply with the 2018 Farm Bill are now eligible for federal trademark protection. However, for a trademark application to be approved, the identification of goods must specify that they contain less than 0.3% THC.
Accordingly, the USPTO makes it clear that its new guidance only applies to goods derived from hemp. “Cannabis and CBD derived from marijuana (i.e., Cannabis sativa L. with more than 0.3% THC on a dry-weight basis) still violate federal law, and applications encompassing such goods will be refused registration regardless of the filing date,” the Examination Guide states.
The USPTO further emphasizes that even if the identified goods are legal under the CSA, such goods may still raise lawful-use issues under the FDCA. Accordingly, registration of marks for foods, beverages, dietary supplements, or pet treats containing CBD will still be refused as unlawful under the FDCA, even if derived from hemp, because they may not be introduced lawfully into interstate commerce.
TTAB Rejects CBD Mark
The new USPTO Examination Guide means that many marks associated with products containing CBD can now be protected. However, as a Colorado cannabis company learned, there are still restrictions.
The TTAB recently ruled that Stanley Brothers Social Enterprises LLC (Stanley) can’t register the mark “CW” for its hemp oil extract because the product can’t legally be sold in commerce. While the CBD in the product is considered industrial hemp, the product runs afoul of the Food, Drug & Cosmetics Act (FDCA) because the “hemp oil extracts” are food to which CBD has been added. The FDCA prohibits “[t]he introduction or delivery for introduction into interstate commerce of any food to which has been added … a drug or biological product for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public ….”
In reaching its decision, the TTAB rejected Stanley’s counterarguments that the 2014 Farm Bill’s Industrial Hemp Provision exempted it from the cited provision of the FDCA and that its goods do not fall within the cited prohibition because they are “dietary supplements” rather than food. “Applicant’s argument that the Industrial Hemp Provision exempts it from this portion of the FDCA is misplaced,” the order states. “The Industrial Hemp Provision permits authorized entities to “grow or cultivate industrial hemp” under certain circumstances, but it does not permit the distribution or sale of CBD in food when CBD is the subject of clinical investigation, even if the CBD is derived from industrial hemp which falls outside the CSA.”
The TTAB also rejected the argument that CBD falls within an FDCA exception for drugs or biological products “marketed in food … before any substantial clinical investigations involving the drug or the biological product have been instituted.” In support, the TTAB cited “substantial clinical investigations” by the FDA.
Based on the foregoing, the TTAB affirmed the Examining Attorney’s unlawful use refusal based on the FDCA. “The Examining Attorney has established a per se violation of the FDCA, because: Applicant’s goods are food to which has been added a drug (CBD); substantial clinical investigations of CBD have been instituted, and the existence of these investigations has been made public; and there is no evidence of record that CBD was marketed in food before the substantial clinical investigations of CBD were instituted,” the TTAB order states.
Key Takeaway
The recent TTAB decision highlights that cannabis companies still face hurdles when seeking to protect their intellectual property. While the 2018 Farm Bill was a significant step forward, it legalized only a specific segment of hemp-related products and, thus, many cannabis products are still ineligible for federal trademark protection.
If you have questions, please contact us
If you have any questions or if you would like to discuss the matter further, please contact me, Dan McKillop, or the Scarinci Hollenbeck attorney with whom you work, at 201-896-4100.
This article is a part of a series pertaining to cannabis legalization in New Jersey and the United States at large. Prior articles in this series are below:
Disclaimer: Possession, use, distribution, and/or sale of cannabis is a Federal crime and is subject to related Federal policy. Legal advice provided by Scarinci Hollenbeck, LLC is designed to counsel clients regarding the validity, scope, meaning, and application of existing and/or proposed cannabis law. Scarinci Hollenbeck, LLC will not provide assistance in circumventing Federal or state cannabis law or policy, and advice provided by our office should not be construed as such.
Let`s get in touch!
Sign up to get the latest from the Scarinci Hollenbeck, LLC attorneys!
